New ALK inhibitor alectinib halts lung cancer growth more than a year longer than crizotinib, with fewer severe side effects

Treating advanced melanoma with ipilimumab and HF10

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers

Immunotherapy may slow the growth of malignant pleural mesothelioma

Immunotherapy for mesothelioma could be on the horizon

CAR T-cell therapy can be used to send multiple myeloma into lasting remission

Alectinib eclipses crizotinib for ALK positive lung cancer

Adding a second HER2 targeted medicine may lower chance of invasive breast cancer

Targeted sequencing in endocrine refractory breast cancer

Results from the APHINITY trial of two HER2 targeted agents with chemo

Treating BRCA breast cancer with PARP inhibition

Relieving spinal cord compression symptoms with a single radiation treatment